OCREVUS® is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features1
OCREVUS® is indicated for the treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity1
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing firstname.lastname@example.org or calling +44 (0)1707 367554. As OCREVUS® is a biological medicine, healthcare professionals should report adverse reactions by brand name and batch number.
AE, adverse event; GB, Great Britain; IRR, infusion related reaction; MoA, mode of action; NI, Northern Ireland; OLE, open label extension; PPMS, primary progressive multiple sclerosis; RMS, relapsing multiple sclerosis.
- OCREVUS® Summary of Product Characteristics (GB and NI).
- Hauser SL et al. N Engl J Med 2017;376(3):221-234.
- Giovannoni G et al. Mult Scler Relat Disord 2016;9 Suppl 1:S5-S48.
- Tintore M. Int MS J 2007;14(1):5-10.
- Montalban X et al. N Engl J Med 2017;376(3):209-220.
Date of preparation: March 2021